D. Bron
Institut Jules Bordet
16 Papers
26 Citations
D. Bron is an academic researcher from Institut Jules Bordet. The author has contributed to research in topics: Copanlisib & Aggressive lymphoma. The author has an hindex of 4, co-authored 16 publications.
Chat about Author
Papers
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Philippe Aftimos,Christian Rolfo,Sylvie Rottey,Fritz Offner,D. Bron,Marie Maerevoet,Jean-Charles Soria,Mahan Moshir,Torsten Dreier,Luc van Rompaey,Jean-Marie Michot,Karen Silence,Anna Hultberg,Domenica Gandini,Hans de Haard,Vincent Ribrag,Marc Peeters,Alain Thibault,Nicolas Leupin,Ahmad Awada +19 more
TL;DR: This dose-escalation phase I trial provides evidence of good tolerability of ARGX-110, pharmacokinetics, and preliminary antitumor activity at all dose levels in generally heavily pretreated patients with advanced CD70-positive malignancies.
Myelofibrosis patients in Belgium: disease characteristics.
Timothy Devos,Pierre Zachee,D. Bron,Lucien Noens,J Van Droogenbroeck,Philippe Mineur,Yves Beguin,Zwi N. Berneman,Fleur Samantha Benghiat,Alain Kentos,Christian Chatelain,Hilde Demuynck,Jan Lemmens,K. Van Eygen,Koen Theunissen,Fabienne Trullemans,Pascal Pierre,Wim Pluymers,Laurent Knoops +18 more
TL;DR: Insight is provided into the characteristics of the Belgian myelofibrosis population and it is suggested that a large proportion of these patients could stand to benefit from the therapies currently under development.
•Journal Article
BHS guidelines for the treatment of marginal zone lymphomas
D. Bron,E. Van Den Neste,Alain Kentos,Fritz Offner,Wilfried Schroyens,Christophe Bonnet,A. Van Hoof,Gregor Verhoef,A Janssens +8 more
TL;DR: This dissertation aims to provide a history of haematology in Belgium from 1989 to 2002, a period chosen in order to explore its roots as well as specific cases up to and including the year in which descriptions of “superficial bleeding” began to emerge.
6
•Journal Article
Guidelines for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and relapsed DLBCL
Gregor Verhoef,Wilfried Schroyens,D. Bron,Christophe Bonnet,V. De Wilde,A. Van Hoof,A Janssens,Daan Dierickx,Marc André,E. Van Den Neste +9 more
TL;DR: The data described below reflect exposure to Tasigna in a total of 717 patients from a randomised Phase III study in patients with newly diagnosed Ph+ CML in chronic phase treated at the recommended dose of 300 mg twice daily.
•Journal Article
BHS guidelines for the treatment of large granular lymphocyte and cronic prolymphocytic leukaemias
C. Springael,Vanessa Delrieu,K.L. Wu,Wilfried Schroyens,Christophe Bonnet,D. Bron,A Janssens +6 more
TL;DR: The optimal treatment strategy should exist of remission induction with alemtuzumab intravenously followed by autologous or allogeneic stem cell transplantation in patients without a p53 mutation and/or a 17p deletion.
3